TY - JOUR
T1 - Biofunctionalized nanoparticles
T2 - an emerging drug delivery platform for various disease treatments
AU - Bose, Rajendran J.C.
AU - Lee, Soo Hong
AU - Park, Hansoo
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.
AB - Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.
UR - http://www.scopus.com/inward/record.url?scp=84975032514&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2016.06.005
DO - 10.1016/j.drudis.2016.06.005
M3 - Review article
C2 - 27297732
AN - SCOPUS:84975032514
SN - 1359-6446
VL - 21
SP - 1303
EP - 1312
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -